BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Mkt (generic) TFF Pharmaceuticals Inc. 8/20/19 $22.0 Preclin Monopar Therapeutics Inc. 8/15/19 $40 Ph II Frontier Biotechnologies Co. Ltd....
BioCentury | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

...lost 2.8%. Frontier to list in Shanghai The Shanghai Stock Exchange accepted an application from Frontier Biotechnologies Co. Ltd....
...company's directional Genomic Hybridization platform assesses cell samples to detect DNA sequences, location and orientation. BioCentury Staff Albuvirtide Frontier Biotechnologies Co. Ltd. KromaTiD...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

...Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., BrightGene Bio-medical Technology Co. Ltd., Bio-Thera Solutions Ltd. and Frontier Biotechnologies Co. Ltd....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jun 8, 2018
Clinical News

Frontier's HIV drug approved in China

...is a long-acting viral entry inhibitor targeting HIV gp41. Frontier Biotechnologies Co. Ltd., Nanjing, China Business: Infectious Jaime De Leon Albuvirtide Frontier Biotechnologies Co. Ltd. HIV...
BioCentury | Jun 5, 2018
Company News

Frontier's HIV drug approved in China

...to originate in China. Albuvirtide is a long-acting viral entry inhibitor targeting HIV gp41. Jaime De Leon Albuvirtide Frontier Biotechnologies Co. Ltd. HIV...
BioCentury | Jan 31, 2017
Distillery Therapeutics

Infectious disease

...and Roche market Fuzeon enfuvirtide, a HIV gp41 viral fusion inhibitor peptide analog, for HIV/AIDS. Frontier Biotechnologies Co. Ltd....
BioCentury | Jan 6, 2017
Financial News

Frontier raises RMB300M in series C

...lamivudine and ritonavir-boosted lopinavir. Albuvirtide is a long-acting viral entry inhibitor targeting HIV gp41 . Becky Simon Albuvirtide Frontier Biotechnologies...
BioCentury | Jan 6, 2017
Financial News

Frontier Biotechnologies completes venture financing

...Group. Shenzhen Capital Group, EFung Capital and undisclosed investors also participated. Frontier Biotechnologies Co. Ltd. , Nanjing, China Alex Himes Frontier Biotechnologies Co. Ltd....
BioCentury | Jul 11, 2016
Clinical News

AB001: Phase II data

...daily in the morning for 14 days. Patches were to be removed after 12 hours. Frontier Biotechnologies Co. Ltd....
Items per page:
1 - 10 of 12
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...Mkt (generic) TFF Pharmaceuticals Inc. 8/20/19 $22.0 Preclin Monopar Therapeutics Inc. 8/15/19 $40 Ph II Frontier Biotechnologies Co. Ltd....
BioCentury | Aug 14, 2019
Financial News

Aug. 14 Financial Quick Takes: Biotech tumbles with markets; plus Frontier, Portola and more

...lost 2.8%. Frontier to list in Shanghai The Shanghai Stock Exchange accepted an application from Frontier Biotechnologies Co. Ltd....
...company's directional Genomic Hybridization platform assesses cell samples to detect DNA sequences, location and orientation. BioCentury Staff Albuvirtide Frontier Biotechnologies Co. Ltd. KromaTiD...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

...Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., BrightGene Bio-medical Technology Co. Ltd., Bio-Thera Solutions Ltd. and Frontier Biotechnologies Co. Ltd....
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Jun 8, 2018
Clinical News

Frontier's HIV drug approved in China

...is a long-acting viral entry inhibitor targeting HIV gp41. Frontier Biotechnologies Co. Ltd., Nanjing, China Business: Infectious Jaime De Leon Albuvirtide Frontier Biotechnologies Co. Ltd. HIV...
BioCentury | Jun 5, 2018
Company News

Frontier's HIV drug approved in China

...to originate in China. Albuvirtide is a long-acting viral entry inhibitor targeting HIV gp41. Jaime De Leon Albuvirtide Frontier Biotechnologies Co. Ltd. HIV...
BioCentury | Jan 31, 2017
Distillery Therapeutics

Infectious disease

...and Roche market Fuzeon enfuvirtide, a HIV gp41 viral fusion inhibitor peptide analog, for HIV/AIDS. Frontier Biotechnologies Co. Ltd....
BioCentury | Jan 6, 2017
Financial News

Frontier raises RMB300M in series C

...lamivudine and ritonavir-boosted lopinavir. Albuvirtide is a long-acting viral entry inhibitor targeting HIV gp41 . Becky Simon Albuvirtide Frontier Biotechnologies...
BioCentury | Jan 6, 2017
Financial News

Frontier Biotechnologies completes venture financing

...Group. Shenzhen Capital Group, EFung Capital and undisclosed investors also participated. Frontier Biotechnologies Co. Ltd. , Nanjing, China Alex Himes Frontier Biotechnologies Co. Ltd....
BioCentury | Jul 11, 2016
Clinical News

AB001: Phase II data

...daily in the morning for 14 days. Patches were to be removed after 12 hours. Frontier Biotechnologies Co. Ltd....
Items per page:
1 - 10 of 12